Fundraising Fox
Sermonix Pharmaceuticals
Columbus, US · Founded 2014 · Delaware corporation
Find your way into Sermonix Pharmaceuticals
79 people in our graph share verified history with the Sermonix Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Isabel Zhangunlockedknows David Portman · together at The Ohio State University Wexner Medical Center (overlapped)
×11knows the team · via The Ohio State University Wexner Medical Center
Sermonix Pharmaceuticals is a privately held biotechnology company developing female-specific oncology products, with a lead investigational drug, lasofoxifene, being studied for breast and ovarian cancer. Its ELAINE study evaluates lasofoxifene versus fulvestrant in women with ER+/HER2- metastatic breast cancer carrying an ESR1 mutation.
Founders & leadership
Sermonix Pharmaceuticals was founded in 2014 by David Portman.
DP
David PortmanFounderDavid Portman is founder and CEO of Sermonix Pharmaceuticals, which develops oncology treatments including lasofoxifene for advanced breast cancer. He conducted over 140 clinical research studies at the Columbus Center for Women's Health Research, which he founded in 1997, focused on women's health including hormone therapy and SERMs, and served as principal investigator for multiple SERM development programs at Pfizer before licensing lasofoxifene from Ligand Pharmaceuticals to establish Sermonix in 2015.
MP
Miriam PortmanChief Operating OfficerMiriam Portman is Chief Operating Officer at Sermonix Pharmaceuticals, a biotechnology company developing oncology treatments for women. She holds a Bachelor's degree in Pre-Medicine from the University of Michigan and has prior experience in pharmaceutical operations.
Funding
SEC filings, press & company announcements$42.8M disclosed across 3 rounds · 2015–2021
- Undisclosed amountSeedNov 2017Source ↗
▶$40.2MraisedNov 2021 · 9 investors · PharmaceuticalsRule 506(b)
▶$40.2MraisedNov 2021 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Anthony WildExecutive Officer, Director
- Miriam PortmanExecutive Officer, Promoter
- Elizabeth AttiasExecutive Officer
- Michael FriedmanDirector
- Simon JenkinsExecutive Officer
- Elizabeth GarnerDirector
- David PortmanExecutive Officer, Director, Promoter
- Richard De SchutterDirector
- Barry KommExecutive Officer
- Thomas PfistererDirector
- Paul PlourdeExecutive Officer
- Offering amount
- $40.2M
- Amount sold
- $40.2M
- Sales commissions
- $2.2M
- Placement agents
- LIFESCI CAPITAL
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedJul 2016 · 2 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedJul 2016 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Miriam PortmanExecutive Officer, Director
- David PortmanExecutive Officer, Director
- Patrick WieselDirector
- Offering amount
- $2.5M
- Amount sold
- $1.6M
- Minimum investment
- $25K
- First sale
- Jul 2016
- Incorporated
- Limited Liability Company, Ohio, 2014
- Federal exemptions
- 06b
▶$1MraisedOct 2015 · 17 investors · PharmaceuticalsRule 506(b)
▶$1MraisedOct 2015 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Miriam PortmanExecutive Officer
- David PortmanExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1M
- Minimum investment
- $50K
- First sale
- Sep 2015
- Incorporated
- Limited Liability Company, Ohio, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Sermonix Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Sermonix Pharmaceuticals do?
- Sermonix Pharmaceuticals is a privately held biotechnology company developing female-specific oncology products, with a lead investigational drug, lasofoxifene, being studied for breast and ovarian cancer. Its ELAINE study evaluates lasofoxifene versus fulvestrant in women with ER+/HER2- metastatic breast cancer carrying an ESR1 mutation.
- Who founded Sermonix Pharmaceuticals?
- Sermonix Pharmaceuticals was founded by David Portman in 2014.
- How much funding has Sermonix Pharmaceuticals raised?
- Sermonix Pharmaceuticals has disclosed $42.8M raised across 3 rounds.
- Where is Sermonix Pharmaceuticals headquartered?
- Sermonix Pharmaceuticals is headquartered in Columbus, US.